
Understanding individual differences in the development of extra-pyramidal side effects (EPS) as a response to antipsychotic therapy is essential to individualize treatment.
Adult, Male, Psychiatric Status Rating Scales, Movement Disorders, Middle Aged, Polymorphism, Single Nucleotide, Repressor Proteins, Schizophrenia, Humans, Female, RNA, Messenger, Myelin Proteolipid Protein, Antipsychotic Agents, Genome-Wide Association Study
Adult, Male, Psychiatric Status Rating Scales, Movement Disorders, Middle Aged, Polymorphism, Single Nucleotide, Repressor Proteins, Schizophrenia, Humans, Female, RNA, Messenger, Myelin Proteolipid Protein, Antipsychotic Agents, Genome-Wide Association Study
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 121 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
